Drug intelligence / Profile preview

BI 1060469 TF2

Development stage: Unknown
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

**BI 1060469 TF2** is a *tablet formulation* of the small molecule drug BI 1060469, developed by Boehringer Ingelheim. BI 1060469 acts as a selective antagonist of **CRTH2 (Prostaglandin D2 receptor 2)**, blocking the effects of prostaglandin D2 (PGD2) in inflammatory pathways[1]. This mechanism is being explored for the treatment of immune system and respiratory diseases, primarily asthma. The "TF2" designation refers to a specific oral tablet formulation, distinguished from earlier prototypes (e.g., TF1), with clinical trials focused on its pharmacokinetics and bioavailability in healthy subjects[2][3][4].

Other names: BI-1060469 TF2BI1060469 TF2BI 1060469 TF2BI 1060469 + TF2

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on BI 1060469 TF2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1060469 TF2.

Explore the full profile